Skip to main content
. 2021 Jul 2;59(1):891–901. doi: 10.1080/13880209.2021.1944224

Figure 2.

Figure 2.

The combination effects of CPT and Bcr-Abl tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of cleaved caspase-3, caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. *p < 0.05, and **p < 0.01 denote significant differences compared with the single TKI treatment group.